| Literature DB >> 30103466 |
Yasuyoshi Miyata1, Tomohiro Matsuo2, Kyohei Araki3, Yuichiro Nakamura4, Yuji Sagara5, Kojiro Ohba6, Hideki Sakai7.
Abstract
Green tea and green tea polyphenols (GTPs) are reported to inhibit carcinogenesis and malignant behavior in several diseases. Various in vivo and in vitro studies have shown that GTPs suppress the incidence and development of bladder cancer. However, at present, opinions concerning the anticancer effects and preventive role of green tea are conflicting. In addition, the detailed molecular mechanisms underlying the anticancer effects of green tea in bladder cancer remain unclear, as these effects are regulated by several cancer-related factors. A detailed understanding of the pathological roles and regulatory mechanisms at the molecular level is necessary for advancing treatment strategies based on green tea consumption for patients with bladder cancer. In this review, we discuss the anticancer effects of GTPs on the basis of data presented in in vitro studies in bladder cancer cell lines and in vivo studies using animal models, as well as new treatment strategies for patients with bladder cancer, based on green tea consumption. Finally, on the basis of the accumulated data and the main findings, we discuss the potential usefulness of green tea as an antibladder cancer agent and the future direction of green tea-based treatment strategies for these patients.Entities:
Keywords: animal model; bladder cancer; epidemiology; green tea; treatment
Year: 2018 PMID: 30103466 PMCID: PMC6164790 DOI: 10.3390/medicines5030087
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Previous reports on the relationship between green tea consumption and bladder cancer risk.
| Case-Control Study | Cohort Study | ||||||
|---|---|---|---|---|---|---|---|
| Author/Year | Daily | OR/RR | 95% CI | Author/Year | Daily | OR/RR | 95% CI |
| Waikens et al. | Cases/controls = 271/522 | Chyou et al. | |||||
| /1996 | (Men) | /1993 | Never | 1.0 | |||
| /USA | Q1 | 1.0 | /USA | Ever | 1.34 | 0.79–2.27 | |
| /[ | Q2 | 1.1 | 0.6−1.9 | /[ | |||
| Q3 | 1.1 | 0.6–2.3 | |||||
| (Women) | Nagano et al. | ||||||
| Q1 | 1.0 | /2000 | 0–1 cup | 1.0 | |||
| Q2 | 0.8 | 0.3–2.1 | /Japan | 2–4 | 1.07 | 0.61–2.00 | |
| Q2 | 0.9 | 0.3–2.6 | /[ | ≥5 | 1.07 | 0.58–2.08 | |
| Wakai et al. | 124/744 | Kurahashi et al. | |||||
| /2004 | < | 1.0 | /2009 | (Men) | |||
| /Japan | 1–4 | 1.40 | 0.74–2.62 | /Japan | <1 cup | 1.0 | |
| /[ | 5–9 | 2.67 | 1.44–4.94 | /[ | 1–2 | 1.18 | 0.73–1.91 |
| ≥10 | 1.18 | 0.49–2.84 | 3–4 | 0.71 | 0.43–1.18 | ||
| ≥5 | 0.90 | 0.56–1.45 | |||||
| Hemelt et al. | 381/371 | (Women) | |||||
| /2010 | 0 | 1.00 | <3 | 1.0 | |||
| /China | <Daily | 0.83 | 0.54–1.27 | 3–4 | 1.22 | 0.49–3.00 | |
| /[ | Daily | 1.02 | 0.71–1.48 | ≥5 | 2.29 | 1.06–4.92 | |
| <4 | 1.23 | 0.76–1.97 | |||||
| ≥4 | 0.83 | 0.53–1.28 | |||||
| Wang et al. | 1007/1299 | ||||||
| /2013 | Never | 1.0 | |||||
| /USA | 0.1–0.13 | 0.82 | 0.61–1.11 | ||||
| /[ | ≥0.14 | 0.60 | 0.45–0.79 | ||||
ref: reference. OR: odds ratio. RR: relative ratio. CI: confidential interval.
Meta-analyses of the relationship between green tea consumption and bladder cancer risk.
| Author/Year | Number of | Number of Cohort Studies | Odds | 95% Confidence |
|---|---|---|---|---|
| Qin et al./2012/[ | 2 | 3 | 0.97 | 0.73–1.21 |
| Wang et al./2013/[ | 2 | 2 | 0.81 | 0.68–0.98 |
| Wu et al./2013/[ | 3 | 2 | 1.03 | 0.82–1.31 |
| Zhang et al./2015/[ | 0 | 3 | 1.02 | 0.95–1.11 |
| Weng et al./2017/[ | 4 | 3 | 0.95 | 0.73–1.24 |
Relationships between green tea polyphenol treatment and various cancer-related functions in in vitro studies of bladder cancer cell lines.
| Cell Line | Type | Dosage/Concentration | Author/Year/Reference |
|---|---|---|---|
| Growth inhibition | |||
| AY-27 | EGCG | >100 μM | Kemberling et al./2003/[ |
| NBT-II | EGCG | 10, 20, or 40 μM/L | Chen et al./2004/[ |
| J82 | EGCG | 70–87 μM | Rieger et al./2007/[ |
| UM-UC-3 | EGCG | 70–87 μM | Rieger et al./2007/[ |
| EJ | EGCG | 70–87 μM | Rieger et al./2007/[ |
| T24 | EGCG | 70–87 μM | Rieger et al./2007/[ |
| KK47 | EGCG | 70–87 μM | Rieger et al./2007/[ |
| TCCSUP | EGCG | 70–87 μM | Rieger et al./2007/[ |
| TSGH-8301 | EGCG | 25–100 μM | Chen et al./2011/[ |
| MBT-2 | EGCG | 12.5–50 μM | Hsieh et al./2011/[ |
| RT4 | EGCG | 60–80 μg/mL | Philips et al./2009/[ |
| SW780 | EGCG | 10–80 μg/mL | Philips et al./2009/[ |
| Apoptosis induction | |||
| NBT-II | EGCG | 10 μM/L | Chen et al./2004/[ |
| T24 | EGCG | 10–80 μg/mL | Qin et al./2007/[ |
| TCCSUP | EGCG | 40 μg/mL | Philips et al./2009/[ |
| TSGH-8301 | EGCG | 75 μM | Chen et al./2011/[ |
| MBT-2 | EGCG | 50 μM | Hsieh et al./2011/[ |
| SW780 | EGCG | 50–200 μM | Luo et al./2017/[ |
| Migration inhibition | |||
| UM-UC-3 | EGCG | 5 μM | Rieger et al./2007/[ |
| EJ | EGCG | 5 μM | Rieger et al./2007/[ |
| TCCSUP | EGCG | 5 μM | Rieger et al./2007/[ |
| SW780 | EGCG | 25–50 μM | Luo et al./2017/[ |
| Cell cycle arrest | |||
| NBT-II | EGCG | 10, 20, or 40 μM/L | Chen et al./2004/[ |
EGCG: epigallocatechin-3-gallate. GTP: green tea polyphenol.
Potential molecular targets of green tea polyphenols in bladder cancer cell lines.
| Molecules | Cell Line | Author/Year/Reference |
|---|---|---|
| Bcl-2 family | T24 | Qin et al./2007/61; Gu et al./2017/[ |
| TSGH-8301 | Chen et al./2011/[ | |
| MBT-2 | Hsieh et al./2011/[ | |
| SW780 | Luo et al./2017/[ | |
| BIU87 | Gu et al./2017/[ | |
| Caspase family | TSGH-8301 | Chen et al./2011/[ |
| MBT-2 | Hsieh et al./2011/[ | |
| SW780 | Luo et al./2017/[ | |
| Cyclin D1 | NBT-II | Chen et al./2004/[ |
| Cyclin-dependent kinase 4/6 | NBT-II | Chen et al./2004/[ |
| Heat shock protein 27 | TSGH-8301 | Chen et al./2011/[ |
| JNK/Bcl-2/Beclin-1 | T24, BIU87 | Gu et al./2017/[ |
| Matrix metalloproteinase-9 | SW780 | Luo et al./2017/[ |
| N-cadherin | UM-UC-3 | Rieger et al./2007/[ |
| Nuclear factor-kappa B | TCCSUP | Philips et al./2009/[ |
| SW780 | Luo et al./2017/[ | |
| Phosphatidylinositol 3-kinase | UM-UC-3 | Rieger et al./2007/[ |
| /Akt signaling | T24 | Qin et al./2007/[ |
| TSGH-8301 | Chen et al./2011/[ | |
| Retinoblastoma protein | NBT-II | Chen et al./2004/[ |
| Wnt signaling | TCCSUP | Philips et al./2009/[ |
Anticancer effects of green tea in animal models of bladder cancer.
| Author/Year/Reference | Agents | Methods | Animal Model | Summary of Results |
|---|---|---|---|---|
| Sato et al./1999/ | GTE | Drinking | Rat; Chemically induced | Dose-dependently inhibited tumor growth when administered after the carcinogen |
| Sato et al./2003/ | GTE | Drinking | Rat; Chemically induced | Prevented tumor growth when administered before the carcinogen |
| Kemberling et al./2003/[ | EGCG | Intra-vesical | Rat; intravesical implantation | Inhibited the growth of transitional carcinoma cells |
| Rieger et al./2007/[ | EGCG | Drinking | Xenograft model | Over 50% decrease in the mean final tumor volume |
| Sagara et al./2010/[ | GTE | Drinking | Mouse; Chemically induced | Inhibited tumor growth and invasion via regulation of angiogenesis |
| Chen et al./2011/[ | ECGC | Gavage | Mouse; xenograft model | Inhibited tumor growth in a dose-dependent manner |
| Hsieh et al./2011/[ | EGCG | Orally, intraperitoneally, | Mouse; injection of cancer cells | EGCG–gold nanoparticles were more effective than free EGCG in inhibiting tumor growth |
| Henriques et al./2014/[ | Whole green tea | Drinking | Mouse; Chemically induced | Influenced inflammation in the urothelium, but not carcinogenesis |
| Matsuo et al./2017/[ | GTE | Drinking | Mouse; Chemically induced | Inhibited tumor growth and angiogenesis via human-antigen R-related pathways |
ref: reference. GTEs: green tea extracts. ECGC: epigallocatechin-3-gallate.